Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04768608
Other study ID # 2020-CAR-00CH2
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date December 23, 2021
Est. completion date May 30, 2023

Study information

Verified date July 2023
Source Zhejiang University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PD1-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer


Description:

Clinical trial for the safety and efficacy of Non-viral programmed cell death protein-1(PD1) integrated anti-prostate-specific-membrane-antigen(PSMA) chimeric antigen receptor T(CART) cells in the treatment of Refractory Castrate-Resistant Prostate Cancer(CRPC)


Recruitment information / eligibility

Status Completed
Enrollment 3
Est. completion date May 30, 2023
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Fully understand and voluntarily sign informed consent. - Aged 18 to 75 years old. - Expected survival > 6 months. - CRPC patients:Serum testosterone reached castration level (<50ng/dl or<1.7nmol/L) and: prostate specific antigen (PSA) increased more than 50% at intervals of one week or three consecutive times, with PSA>2 ng/ml; or imaging scans revealed two or more new lesions or enlargement of soft tissue lesions that met the criteria for evaluating solid tumor response. - CRPC patients received abiraterone or chemotherapy for 3 months or more, and were ineffective or progressive (PSA continued to rise for 3 months, or bone scan/whole-body imaging showed local recurrence or new metastasis). - Immunohistochemical staining of repetitive biopsy tissues showed the expression of PSMA in tumor cells was more than 50%. - Eastern Cooperative Oncology Group (ECOG) score =2. - Virological examination was negative. - Hematological indexes: hemoglobin > 100 g/L, platelet count > 100×10^9/L, absolute neutrophil count > 1.5×10^9/L. Exclusion Criteria: - Prior treatment with any CART therapy targeting any target. - Prior treatment with any PSMA targeting therapy. - Need steroid therapy, except physiological replacement therapy. - Prior treatment with any immunotherapy, including tumor vaccine therapy, radium-223, checkpoint inhibitors and others. - Subjects with severe mental disorders. - Subjects with other malignant tumors. - Subjects with severe cardiovascular diseases: a, New York Heart Association (NYHA) stage III or IV congestive heart failure; b, history of myocardial infarction or coronary artery bypass grafting (CABG) within 6 months; c, clinical significance of ventricular arrhythmia, or history of unexplained syncope, non-vasovagal or dehydration; d, history of severe non-ischemic cardiomyopathy; e, the left ventricular ejection fraction (left ventricular ejection fraction< 55%) was decreased by echocardiography or multiple gated acquisition scan (within 8 weeks before peripheral blood mononuclear cell (PBMC) collection), and abnormal interventricular septal thickness and atrioventricular size associated with myocardial amyloidosis. - Patients with ongoing or active infection. - Organ function: a, Alanine aminotransferase or Aspartate aminotransferase >2.5*Upper limit of normal (ULN); Creatine kinase>1.5*ULN; Creatine kinase isoenzyme >1.5*ULN; Troponin T >1.5*ULN; b, Total bilirubin >1.5*ULN; c, Partial prothrombin time or activated partial thromboplastin time or international standardized ratio > 1.5*ULN without anticoagulant treatment. - History of participation in other clinical studies within 3 months or treatment with any gene therapy product. - Intolerant or allergic to cyclophosphamide or fludarabine. - Subjects not appropriate to participate in this clinical study judged by investigators.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PD1-PSMA-CART cells
PD1-PSMA-CART cells will be given IV at split doses

Locations

Country Name City State
China The First Affiliated Hospital, Zhejiang University Hangzhou Zhejiang

Sponsors (2)

Lead Sponsor Collaborator
Zhejiang University Bioray Laboratories

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of toxicity graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events All adverse events (AEs) will be listed and summarized. Summaries of laboratory data will include, at a minimum, treatment-emergent laboratory abnormalities. Summaries of AEs and laboratory abnormalities will be based on the All Treated analysis set. 28 days
Secondary Prostate specific antigen (PSA) response rate proportion of patients with =50% PSA decline from baseline at any time point after therapy and maintained for =4weeks 180 days
Secondary Radiographic response rate by RECIST 1.1 & PCWG3 Proportion of patients with a best response of either complete response or partial response, assessed using Prostate Cancer Working group3(PCWG3) response criteria & Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 180 days
Secondary Number of persistent CART cells detected by Quantitative Real-time Polymerase Chain Reaction or flow cytometry Number of persistent CART cells detected by Quantitative Real-time Polymerase Chain Reaction or flow cytometry 180 days
See also
  Status Clinical Trial Phase
Completed NCT02814669 - Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor Phase 1
Completed NCT02259114 - A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) Phase 1
Completed NCT01234025 - Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) Phase 1/Phase 2
Completed NCT00770848 - AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer Phase 1/Phase 2
Completed NCT01599793 - Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer Phase 2
Terminated NCT01083615 - A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Phase 3
Suspended NCT04053062 - LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer Phase 1
Terminated NCT01717898 - A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer Phase 1/Phase 2
Completed NCT01824342 - Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer Phase 3
Completed NCT00838201 - Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer Phase 3